RO 6874281

Drug Profile

RO 6874281

Alternative Names: aFAP-IL2v; FAP-IL2v; FAP-IL2v FP; RG 7461; RO6874281

Latest Information Update: 27 Apr 2016

Price : $50

At a glance

  • Originator Roche
  • Class Antibodies; Antineoplastics; Interleukins; Recombinant fusion proteins
  • Mechanism of Action Fibroblast activation protein antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 16 Apr 2016 Pharmacodynamics data from a preclinical study in Solid tumours presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 11 Dec 2015 Roche plans a phase I trial in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Netherlands and Spain (IV) (NCT02627274)
  • 01 Nov 2015 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Denmark (IV) (NCT02627274)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top